$XAIR

Lin Yi-Chien purchased $6K of XAIR

Lin Yi-Chien purchased 2,607 shares of Beyond Air, Inc. (XAIR) at $2.21 on 2026-10-13.

Original reporting
SEC EDGAR · Lin Yi-Chien
Published Oct 14, 2026, 4:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 4:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$XAIR
Neutral
medium confidence
Mentioned
$XAIR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$XAIRNeutralLow
01

Why it matters

The modest purchase is unlikely to move the stock significantly but may be noted by short-term traders.

02

Market read

A small insider buy provides a low‑impact, low‑novelty signal for traders monitoring XAIR.

03

What to watch

Potential upcoming financing or strategic moves not disclosed yet could make the insider's stake more significant.

Relevance 4/10Novelty 4/10Timing: after-hours filing

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of this purchase.

Company-level read

Ticker impact

$XAIRNeutralMedium confidence
Context

Insider Lin Yi-Chien bought 2,607 shares of Beyond Air at $2.21 each, increasing holdings to 148,000 shares.

Expected impact

slight upward pressure as market views insider confidence positively

Evidence & confidence

The transaction size (~$5.8k) is minor for a public float, so any price effect will be limited.

Market effects

Minimal impact on the broader aerospace/ UAV sector.

No regional effect.

Not relevant globally.

Counterpoint

The purchase may be routine portfolio rebalancing, not a signal of material change.

Key entities

  • Beyond Air, Inc.

    UAV and air mobility company listed on NASDAQ under ticker XAIR.

  • Lin Yi-Chien

    10% owner of Beyond Air who executed the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$XAIRMed

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026

Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air ® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last ye

$XAIRMed

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air ® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement fo

$XAIRMed

Beyond Air, Inc. Q1 2027 Earnings Call Summary

Beyond Air, Inc. reported Q1 2027 revenue of $1.8 million, citing long hospital contracting cycles. Management said its sales pipeline doubled and secured a national GPO agreement. It reaffirmed 2026 revenue guidance of $8 million and projected 2027 revenue of $16-$18 million, tied to Gen II LungFit PH FDA timing. A $30 million financing supports Gen II launch.

$XAIRMed

Beyond Air (XAIR) Q1 2027 Earnings Call Transcript

Beyond Air (XAIR) held a Q1 2027 earnings call. It reported Q ended June 30, 2026 revenue of $1.8 million, flat vs the prior quarter, with gross margin rising to 13% from 9%. The company reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million, pending FDA approval for its Gen II LungFit PH system. It also entered a national GPO deal and announced financing up to $30 million.

$XAIRMedAI 8/10

Beyond Air Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

Beyond Air (NASDAQ: XAIR) reported Q2 2026 revenue of $1.8 million and gross margin of 13%. It reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16-$18 million, including second-generation LungFit PH revenue pending FDA approval. The company is awaiting FDA review of a PMA supplement, expects a decision in 2H 2026, and raised up to $30.1 million.